Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

December 13, 2005

Primary Completion Date

March 11, 2018

Study Completion Date

March 11, 2018

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

rituximab

Given IV

DRUG

bortezomib

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

prednisone

Given orally

Trial Locations (8)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

11725

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack

30322

Winship Cancer Institute of Emory University, Atlanta

07920

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge

08903

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick

Unknown

Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre

Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

collaborator

Columbia University

OTHER

collaborator

Emory University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00295932 - Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter